Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer

An analysis of the worldwide utilisation of haematopoietic stem cell transplantation for acute myeloid leukaemia

Opinion: Premature regulatory approval by the FDA

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R follicular lymphoma

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma

Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma

HER2DX confirms the ability of the test to predict long-term survival and response to anti-HER2 therapy in BC

Treatment decision guided by CTC count may improve long-term outcomes for mBC

The future of precision oncology

The concept of pan-tumour therapeutics

Access to Oncology Medicines Coalition - The Medicines Patent Pool